ARO次世代医療センター

Medicine and Dentistry

1. Patient 100%
2. Therapeutic Procedure 30%
3. Inpatient 25%
4. Combination Therapy 20%
5. Non Small Cell Lung Cancer 16%
6. Heart Failure 13%
7. Progression Free Survival 12%
8. Overall Survival 12%
9. Clinical Trial 12%
10. Cardiovascular System 10%
11. Lung Cancer 9%
12. Cells 8%
13. Neoplasm 8%
14. Epidermal Growth Factor Receptor 8%
15. Carboplatin 8%
16. Skill 8%
17. Development 7%
18. Analysis 7%
19. Arm 7%
20. Pemetrexed 7%
21. Surgery 7%
22. Association 7%
23. Age 7%
24. Adverse Event 7%
25. Cardiovascular Disease 6%
26. Maturity Onset Diabetes of the Young 6%
27. Blood Pressure 6%
28. Lipid 6%
29. Hazard Ratio 6%
30. Assessment 6%
31. Surgeon 6%
32. Plasma 6%
33. Suture Material 6%
34. Family 6%
35. Rosuvastatin 6%
36. Female 6%
37. Alzheimer's Disease 5%
38. Atezolizumab 5%
39. Survival Rate 5%
40. Chemotherapy 5%
41. Chemoradiotherapy 5%
42. Osimertinib 5%
43. Phase II Trials 5%
44. Survival 5%
45. Bevacizumab 5%
46. Epidermal Growth Factor Receptor 5%
47. Diseases 5%
48. Paclitaxel 5%
49. Platinum 5%
50. Disease Exacerbation 5%
51. Atrial Fibrillation 5%
52. Follow up 5%

Pharmacology, Toxicology and Pharmaceutical Science

1. Paclitaxel 11%
2. Clinical Trial 11%
3. Non Small Cell Lung Cancer 10%
4. Progression Free Survival 10%
5. Adverse Event 8%
6. Osimertinib 7%
7. Lung Cancer 7%
8. Angiotensin Receptor Antagonist 7%
9. Carboplatin 7%
10. Overall Survival 6%
11. Epidermal Growth Factor Receptor 6%
12. Warfarin 6%
13. Liver Cirrhosis 6%
14. Toxicity 6%
15. Congestive Cardiomyopathy 6%
16. Chronic Thromboembolic Pulmonary Hypertension 6%
17. Statin (Protein) 5%
18. Atrial Fibrillation 5%
19. Diseases 5%
20. Deterioration 5%
21. Heart Failure 5%
22. Pitavastatin 5%